# A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Source: https://onco.cc/trials/nct02972840/  
OnCo record `nct02972840` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Acalabrutinib, Bendamustine and Rituximab in mantle cell lymphoma, run by Acerta Pharma BV, active and no longer recruiting.

## Summary

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL is a phase 3 interventional study registered as NCT02972840 by Acerta Pharma BV, with 635 participants enrolled, started 2017-04-05 and due to reach its primary completion in 2027-02-15. Interventions recorded: Acalabrutinib, Bendamustine, Rituximab and Placebo.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02972840
- Phase: 3
- Setting: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma
- Sponsor: Acerta Pharma BV
- Enrolled: 635

## Sources

- ClinicalTrials.gov NCT02972840: https://clinicaltrials.gov/study/NCT02972840

## Connected records

- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Bendamustine](https://onco.cc/drugs/bendamustine/), [Rituximab](https://onco.cc/drugs/rituximab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct02972840.json